Combination chemotherapy with CCNU (NSC-79037),hexamethylmelamine (NSC-13875) and methotrexate (NSC-740) in advanced bronchogenic carcinoma.
18 patients with metastatic or recurrent bronchogenic carcinoma and one patient with a squamous cell carcinoma of the trachea were treated with a combination of CCNU, hexamethylmelamine and methotrexate. Objective remissions were observed in 3/19 (16%): 1 complete, 1 partial (greater than 50%) and 1 incomplete (less than 50%). However, the patient with the complete response was the only drug death, on day 21. Remission duration in the other two patients was 3 and 9+ months respectively. One patient with oat cell carcinoma experienced no tumor progression for 5 months. This combination resulted in severe gastrointestinal toxicity in 5/19, severe thrombopenia in 12/19 and severe neutropenia in 6/19. We conclude that the combination as used here resulted in no increased clinical effectiveness and proved to be quite toxic.
D000368:Aged; D006585:Altretamine / Q000627:therapeutic use*; D002283:Carcinoma, Bronchogenic / Q000188:drug therapy*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008130:Lomustine / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use*; D008875:Middle Aged; D009607:Nitrosourea Compounds / Q000627:therapeutic use*; D012075:Remission, Spontaneous; D014134:Tracheal Neoplasms / Q000188:drug therapy; D014227:Triazines / Q000627:therapeutic use*
D009607:Nitrosourea Compounds; D014227:Triazines; D008130:Lomustine; D006585:Altretamine; D008727:Methotrexate